Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

    Welcoming the EMA's approval of daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly register daclatasvir in those countries with a high burden of hepatitis C, especially in those countries with a high prevalence of genotype 3. It also urged BMS to ensure daclatasvir is affordable in those countries with a high burden of hepatitis C.

    01 September 2014 | Pharmabiz
  • Stock-out hits HIV treatment across India

    Treatment for HIV patients across India has taken a hit, especially in Delhi and Mumbai, due to severe stock-outs of life-saving medicines reported at government-owned centres.

    26 August 2014 | Times of India
  • The Risky Business of Limiting Medicaid Access to Sovaldi

    Partially because of its high cost, nearly half the states are restricting Medicaid patients' access to an effective new hepatitis C drug. Experts say there’s no question lawsuits will come.

    21 August 2014 | Governing
  • Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

    Share Tools Comment Print Contact Author Reprint Indian drugmakers have a shot at bringing Gilead Sciences' ($GILD) hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi (sofosbuvir) to that country and other developing nations at a fraction of the U.S. price.

    11 August 2014 | Fierce Pharma
  • MSF: Untangling the web of antiretroviral price reductions, 17th Edition

    This 17th edition of Untangling the Web of Antiretroviral Price Reductions is a departure from recent previous years. The information is presented in a new, shorter format focusing on a few key drugs as well as future regimens, along with an analysis of the current opportunities, challenges and threats faced in keeping the price of ARVs down.

    08 August 2014 | MSF
  • Even With Obamacare, HIV Patients Are Shouldering A Huge Portion Of Their Treatment Costs

    While the Affordable Care Act (ACA) forbids insurance companies from refusing coverage to people with preexisting conditions, many providers have categorized special drugs — including those that treat HIV — so that patients shoulder as much as 50 percent of the total cost.

    08 August 2014 | ThinkProgress
  • Heightened HIV risk for people with disabilities

    Inaccessible health services for people with disabilities (PWD), combined with social stigma and violence, contribute to high HIV risk - a gap that must be filled if the disabled are not to remain disproportionately vulnerable to HIV/AIDS, say health experts and activists.

    31 July 2014 | IRIN Plus News
  • Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond

    Together with many large NGOs EATG has signed up to a Joint Declaration urging EU Ministries of health to consider compulsory licensing as a last resort to ensure access to the HCV direct-acting antivirals.

    30 July 2014 | EATG
  • Maximizing the benefits of antiretroviral therapy for key populations

    “Maximizing the benefits of ART for key populations” grew out of discussions between the Key Affected Populations and Treatment as Prevention Working Groups of the International AIDS Society. The two groups agreed that given the rapidly changing treatment and prevention landscape in HIV, there was a need to consider a range of issues affecting treatment access, prevention choices, and the implications of new guidelines for key populations.

    24 July 2014 | International AIDS Society
  • AIDS 2014: Financing the new global HIV treatment vision – advocacy and economics

    The USAID- and PEPFAR-funded Health Policy Project’s own estimates of the global costs of reaching extremely high levels of ART coverage in low and middle-income countries suggest that between U.S.$5.5 to $9 billion might be required annually to meet this goal by 2020.

    24 July 2014 | Science Speaks
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.